Keri Mullins
Family · Oblong, ILNPI 1710143367
Payments from drug & device makers
Across 74 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$191
- Otsuka America Pharmaceutical, Inc.$148
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
- Lundbeck LLC$137
- Neurocrine Biosciences, Inc.$105
- Lilly USA, LLC$73
- plus $538 from 14 others
What the payments were for
- Food & beverage$1,334100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $191 |
| Otsuka America Pharmaceutical, Inc. | 8 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $142 |
| Lundbeck LLC | 7 | $137 |
| Neurocrine Biosciences, Inc. | 6 | $105 |
| Lilly USA, LLC | 5 | $73 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $60 |
| Alkermes, Inc. | 3 | $56 |
| Johnson & Johnson | 3 | $48 |
| Amgen | 2 | $46 |
| Harmony Biosciences LLC | 2 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Corium, LLC | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| GSK | 1 | $16 |
How this compares
$1,334 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $44,768 |
| EliquisApixaban | 59 | $26,601 |
| RybelsusSemaglutide | 26 | $23,833 |
| TrulicityDulaglutide | 22 | $21,078 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $18,341 |
| MounjaroTirzepatide | 13 | $16,692 |
| GlyxambiEmpagliflozin/Linagliptin | 22 | $13,779 |
| JanuviaSitagliptin Phosphate | 23 | $13,757 |
| XareltoRivaroxaban | 16 | $13,734 |
| TradjentaLinagliptin | 24 | $11,853 |
| Arnuity ElliptaFluticasone Furoate | 33 | $8,615 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,031 |
| InvokanaCanagliflozin | 12 | $6,755 |
| MyrbetriqMirabegron | 13 | $6,534 |
| Solifenacin Succinate | 39 | $3,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $42 | $70,401112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $73 | $37,77035 claims |
| GSKBreo Ellipta, Arnuity Ellipta, Incruse Ellipta | $16 | $33,98697 claims |
| Novo NordiskRybelsus | $17 | $23,83326 claims |
| Johnson & JohnsonXarelto, Invokana | $48 | $20,49028 claims |
| AbbVieSynthroid | $191 | $1,43428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.
Other family in Oblong
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.